Methods of synthesis
How were the studies combined?
The studies were grouped according to eight questions about the effectiveness of APAP, and were combined in a descriptive summary within these groups.
How were differences between studies investigated?
The tables of the included studies showed differences between the studies in terms of the APAP device used, patient characteristics, outcomes and potential sources of bias. Some of these differences were highlighted in the text that summarised the evidence for each of the clinical questions addressed.
Results of the review
Thirty articles were included. These reported 13 crossover RCTs (n=329), 8 parallel-group RCTs (n=254), one non-RCT (n=15), 11 clinical series with an historical control (n = about 200) and one case report.
Only 3 of the included studies were rated as providing level I evidence; the majority of the other evidence was level II or IV (see Other Publications of Related Interest). The main findings for each of the questions addressed are summarised here. Can APAP effectively reduce the apnoea plus hypopnea index (AHI) in OSA patients? APAP reduced the AHI to acceptable levels (less than 10 per hour) in more than 80 to 95% of the OSA patients studied in 16 RCTs, one non-randomised trial and 9 clinical series. The RCTs, however, were not designed to answer this question and none had a placebo control group. None of the studies included patients with significant central apnoea, and most excluded patients with congestive heart failure or chronic lung disease.
Can APAP reduce the AHI as well as conventional CPAP, in laboratory titration or as chronic treatment? Is the mean pressure lower on APAP devices?
In 12 RCTs, one non-RCT and 3 clinical series, similar AHIs were shown on treatment nights with APAP compared with nights on fixed CPAP. The mean or median treatment pressure was lower with APAP than with CPAP in 9 studies, and was higher in one study.
Can APAP effectively improve sleep quality and subjective and objective measures of daytime sleepiness in OSA patients?
Eleven RCTs, one non-RCT and 4 clinical series found some evidence that APAP improved sleep quality. An improvement in subjective measurement of daytime sleepiness, assessed using the Epworth Sleepiness Scale (ESS), was found with both APAP and CPAP in 4 crossover and 3 parallel-group RCTs; these also found no significant difference between APAP and CPAP. The only non-RCT found no improvement in ESS after one month' APAP when compared to baseline. The objective measures of daytime sleepiness reported were sleep latency (Multiple Sleep Latency Test improved in one clinical series) and the maintenance of wakefulness test latency (similarly improved with APAP and CPAP in 2 parallel-group RCTs).
Can APAP prevent significant nocturnal oxygen desaturation?
The evidence from various studies, which used different indices of arterial oxygen saturation, suggests that APAP prevents significant oxygen desaturation in most patients with OSA.
Are all APAP technologies equally effective?
No studies that met the inclusion criteria compared different APAP technologies.
Is APAP effective in determining an optimal fixed CPAP pressure for chronic fixed CPAP treatment during an attended or unattended APAP titration? Does APAP titration affect acceptance or adherence?
Four RCTs (2 of attended titration, one unattended, 1 partially attended) and 3 clinical series (one attended, 2 unattended) found that APAP could be used to select a fixed CPAP pressure that reduced the AHI to less than 10 per hr in up to 95% of the patients studied. One RCT suggested that using APAP to define a fixed pressure for treatment, rather than traditional CPAP, decreased the percentage of patients who declined to continue CPAP treatment at 6 weeks.
Does auto-CPAP increase the acceptance or utilisation with positive pressure treatment when used as long-term treatment for OSA?
The available evidence was inconsistent.
Are there safety considerations in selecting patients for auto-CPAP titration or treatment?
Only 2 studies specifically addressed safety. One was a case report that described the appearance of central apnoeas that occurred as pressure was increased during APAP titration. In one clinical series, complications including central apnoea with arrhythmia and hypoxemia were reported in 6 out of 21 patients with congestive heart failure or lung disease undergoing CPAP titration; however, the device used was not a true APAP unit.
Authors' conclusions
The data indicated that APAP can be used to treat many patients with OSA (self-adjusting), or to identify an optimal fixed level of CPAP for treatment (auto-titration).
CRD commentary
This review addressed many questions about more than one application of the intervention of interest; this could be why the inclusion criteria were broadly defined rather than explicit. Two databases were searched but inclusion was limited to articles published in English in peer-reviewed journals, so it is possible that relevant studies were missed. Since details of how the studies were selected for inclusion were not reported, there is no reassurance that steps were taken to minimise bias. Furthermore, it is implied that some articles were included on the basis of the results they reported, which adds doubt that the study selection process was systematic and unbiased throughout. The included studies were presented clearly in tabular format, but there were insufficient details to assess whether the validity assessment and data extraction were methodologically sound. A narrative synthesis was appropriate given the differences between the studies. The findings were interpreted in the context of study design and the features of the participants, intervention and outcomes that might have influenced the results.
The authors' main conclusion is too general considering that it encompasses several review questions for which there were varying degrees of evidence, and the limitations inherent in the designs of the studies on which it was based.
Implications of the review for practice and research
Practice: The authors state that there is insufficient evidence that APAP can be used to treat patients with significant congestive heart failure, chronic obstructive pulmonary disease, or significant amounts of central apnoea.
Research: The authors recommendations for future research are many, some are listed here and the others can be found in the report. Further studies are needed to determine the effectiveness of APAP in mild OSA; to determine the safety and efficacy of initial titration of APAP in CPAP-naive patients in an unattended setting; and to determine whether chronic treatment with APAP can increase acceptance or adherence with positive pressure treatment. No study has yet shown that APAP improves patient outcomes. There is little information on the safety of unattended APAP in at-risk patient groups, and more information is needed on patients who need high levels of CPAP. There are few data comparing different APAP technologies.
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